Onartuzumab is a humanized single-arm anti-MET antibody blocking the binding of the HGF α-chain to MET, which performed poorly in a phase III study examining the efficiency of erlotinib with or without onartuzumab in patients with MET-positive locally advanced or metastatic NSCLC [257, 258]. The gene discussed is HGF; the disease is non-small cell lung carcinoma.